Alison Schneider, MD
Endocrinology, Diabetes & Metabolism · Kalispell, MTNPI 1124184411
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $306 of the $380 with a category attached, or 80.5%. It is spread thinly across 14 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.
Across 19 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$65
- Sanofi-aventis U.S. LLC$60
- Amgen$39
- Novo Nordisk$31
- Ferring Pharmaceuticals Inc.$27
- Tandem Diabetes Care, Inc.$26
- plus $131 from 8 others
Across 12 payments — averaging $13,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$157K
What the payments were for
- Speaking & faculty fees$6016%
- Food & beverage$30681%
- Education$144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 4 | $65 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Amgen | 2 | $39 |
| Novo Nordisk | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $27 |
| Tandem Diabetes Care, Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $18 |
| Abbott | 1 | $15 |
| Medtronic | 1 | $15 |
| AbbVie | 1 | $14 |
| Merck | 1 | $12 |
| AstraZeneca | 1 | $12 |
How this compares
Too few endocrinology, diabetes & metabolism providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 161 | $225,106 |
| MounjaroTirzepatide | 101 | $159,731 |
| JardianceEmpagliflozin | 79 | $113,708 |
| TrulicityDulaglutide | 46 | $81,515 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $66,754 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $41,581 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $33,109 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 153 | $27,537 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $26,566 |
| Novolog FlexpenInsulin Aspart | 78 | $26,254 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $23,440 |
| FarxigaDapagliflozin Propanediol | 20 | $23,252 |
| Humalog Kwikpen U-100Insulin Lispro | 59 | $22,196 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $21,622 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $16,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $65 | $241,247147 claims |
| Novo NordiskOzempic, Novolog | $31 | $230,798175 claims |
| Boehringer IngelheimJardiance | $18 | $113,70879 claims |
| AstraZenecaFarxiga | $12 | $23,25220 claims |
| MerckJanuvia | $12 | $16,85313 claims |
| Sanofi-aventis U.S. LLCLantus | $60 | $3,63515 claims |
| AbbVieSynthroid | $14 | $2,42024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Montanaon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Kalispell
- Jose DesouzaKalispell$454
- Mary Irene Beatrice FeriaKalispell$303
- Barry CohanGreat Falls$11K
- Heidi Peynado de PenaGreat Falls$5K
- Lauren KleessBillings$1K
- Bhanu PaturiBozeman$996
- Christopher CorsiMissoula$978
- Michael SalimGreat Falls$846
- Michele DanicichMissoula$799
- Meredith RossMissoula$582
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.